Search

Your search keyword '"Cai, Haixia"' showing total 16 results
Start Over Author "Cai, Haixia" Publication Year Range Last 10 years
16 results on '"Cai, Haixia"'

3. Prevalence, Contemporary Trends and Associated Factors of Potentially Inappropriate Prescription of Edoxaban in Real‐world Clinical Practice: A Subanalysis of the SUNSHINE Registry

Author

Zhao, Shujuan, primary, Dai, Hengfen, additional, Chen, Jiaxin, additional, Ni, Ming, additional, Peng, Wenxing, additional, Li, Xiaoyu, additional, Li, Fen, additional, Chen, Boya, additional, Cai, Haixia, additional, Liu, Yinping, additional, Gu, Zhichun, additional, Du, Song, additional, and Ma, Peizhi, additional

Published
2023
Full Text
View/download PDF

8. Prevalence, contemporary trends and associated factors of potentially inappropriate prescription of edoxaban in real‐world clinical practice: A subanalysis of the SUNSHINE registry.

Author

Zhao, Shujuan, Dai, Hengfen, Chen, Jiaxin, Ni, Ming, Peng, Wenxing, Li, Xiaoyu, Li, Fen, Chen, Boya, Cai, Haixia, Liu, Yinping, Gu, Zhichun, Du, Song, and Ma, Peizhi

Subjects
AMIODARONE, INAPPROPRIATE prescribing (Medicine), EDOXABAN, ORAL medication, OFF-label use (Drugs), CHINESE people
Abstract

Aim: As the direct oral anticoagulant most recently approved in China, data pertaining to clinical edoxaban use are still scarce. This study investigated the prevalence of and contemporary trends in edoxaban prescription among Chinese patients as well as factors associated with its inappropriate use in a multicentre registry of patients treated in real‐world clinical practice. Methods: This real‐world, prospective, multicentre and non‐interventional study included 1005 inpatients treated with edoxaban. According to National Medical Products Administration and European Heart Rhythm Association guidelines, edoxaban therapy was determined to be appropriate or inappropriate in each case. Results: The median patient age was 70.0 years (interquartile range 61.0‐78.0 years) and 46.3% were women. Overall, 456 (45.4%) patients received inappropriate edoxaban therapy, and common issues included an inappropriately low dosage (183, 18.2%) or wrong drug selection (109, 10.8%), high dosage (73, 7.3%), unreasonable off‐label use (49, 4.9%), contraindicated medication combinations (27, 2.7%) and incorrect administration timing (16, 1.6%). Several factors, such as age ≥75 years (odds ratio [OR] = 1.921, 95% confidence interval [CI] 1.355‐2.723, P < 0.001), weight >60 kg (OR = 2.657, 95%CI 1.970‐3.583, P < 0.001), severe renal insufficiency (OR = 1.988, 95% CI 1.043‐3.790, P = 0.037), current anaemia (OR = 1.556, 95% CI 1.151‐2.102, P = 0.004) and history of bleeding (OR = 2.931, 95% CI 1.605‐5.351, P < 0.001) were associated with an increased risk of inappropriate edoxaban therapy, whereas factors associated with cardiovascular specialties, such as admission to a cardiovascular department (OR = 0.637, 95% CI 0.464‐0.873, P = 0.005), dronedarone use (OR = 0.065, 95% CI 0.026‐0.165, P < 0.001) and amiodarone use (OR = 0.365, 95% CI 0.209‐0.637, P < 0.001) decreased this risk. Conclusion: In this real‐world study, 45.4% of patients received an inappropriate treatment with edoxaban. Multiple clinical characteristics can help identify patients who should receive edoxaban. Further development and implantation of educational activities and management strategies are needed to ensure the correct use of edoxaban. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Real-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database

Author

Cai, Haixia, Jia, Beixi, Fu, Zhonghua, Chen, Boya, Liu, Yinping, and Zhao, Shujuan

Abstract

ABSTRACTBackgroundThe triglyceride-lowering drug, icosapent ethyl (IPE), was granted a new indication for the reduction of atherosclerotic cardiovascular disease risk in 2019. This study aimed to investigate the safety profile of IPE by mining the FDA Adverse Event Reporting System (FAERS) database.MethodsThe reporting odds ratio was used to analyze IPE’s adverse events (AEs) based on the FAERS data from July 2012 to December 2022. We described the characteristics of AE reports and evaluated the clinical prioritization of AEs. Then we defined and analyzed nine interested adverse drug reactions (ADRs) in both overall and subgroups, and investigated the times to onset.ResultsThe findings of our study strengthen the evidence for an increased risk of atrial fibrillation using IPE. IPE alone may not increase the risk of bleeding unless combined with antithrombotic drugs. Similar to statins, IPE alone can increase the risk of musculoskeletal pain, drug-related hepatic disorders, and hyperglycemia, but the risk could not double when IPE was combined with statins. Most ADRs occur in the early stage of treatment.ConclusionsThis study provides a comprehensive real-world safety profile of IPE, which indicates that IPE is well-tolerated.

Published
2024
Full Text
View/download PDF

15. Factors influencing medication knowledge and beliefs on warfarin adherence among patients with atrial fibrillation in China

Author

Zhao,Shujuan, Zhao,Hongwei, Wang,Xianpei, Gao,Chuanyu, Qin,Yuhua, Cai,Haixia, Chen,Boya, Cao,Jingjing, Zhao,Shujuan, Zhao,Hongwei, Wang,Xianpei, Gao,Chuanyu, Qin,Yuhua, Cai,Haixia, Chen,Boya, and Cao,Jingjing

Abstract

Shujuan Zhao,1 Hongwei Zhao,1 Xianpei Wang,2 Chuanyu Gao,2 Yuhua Qin,1 Haixia Cai,1 Boya Chen,1 Jingjing Cao1 1Department of Pharmacy, 2Department of Cardiovascular Medicine, People’s Hospital of Henan Province, Zhengzhou, Henan, People’s Republic of China Objectives: Warfarin is often used for ischemic stroke prevention in patients with atrial fibrillation (AF), but the factors affecting patient adherence to warfarin therapy have not been fully understood. Methods: A cross-sectional survey was conducted in AF patients undergoing warfarin therapy at least 6 months prior to the study. The clinical data collected using questionnaires by phone interviews included the following: 1) self-reported adherence measured by the Morisky Medication Adherence Scale-8©; 2) beliefs about medicines surveyed by Beliefs about Medicines Questionnaire (BMQ); and 3) drug knowledge as measured by the Warfarin Related Knowledge Test (WRKT). Demographic and clinical factors associated with warfarin adherence were identified using a logistic regression model. Results: Two hundred eighty-eight patients completed the survey and 93 (32.3%) of them were classified as nonadherent (Morisky Medication Adherence Scale-8 score <6). Major factors predicting warfarin adherence included age, cardiovascular disorders, WRKT, and BMQ; WRKT and BMQ were independently correlated with adherence to warfarin therapy by multivariate logistic regression analysis. Adherents were more likely to have greater knowledge scores and stronger beliefs in the necessity of their specific medications ([odds ratio {OR} =1.81, 95% confidence interval {CI} =1.51–2.15] and [OR =1.17, 95% CI =1.06–1.29], respectively). Patients with greater concerns about adverse reactions and more negative views of general harm were more likely to be nonadherent ([OR =0.76, 95% CI =0.69–0.84] and [OR =0.82, 95% CI =0.73–0.92], respectively). Conclusion: BMK and WRKT are

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results